Annual report
4078.TEDINET S100Q013
Period2018-04-01 → 2019-03-31
Filed2023-01-23
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amends S100G06X.
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥89.5bn | 2018-04-01 → 2019-03-31 | Cons. | Net sales |
| Revenue | ¥87.2bn | 2017-04-01 → 2018-03-31 | Cons. | Net sales |
| Revenue | ¥83.9bn | 2016-04-01 → 2017-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥85.5bn | 2015-04-01 → 2016-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥87.0bn | 2014-04-01 → 2015-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥4.4bn | 2018-04-01 → 2019-03-31 | Cons. | Operating income |
| Operating income | ¥4.7bn | 2017-04-01 → 2018-03-31 | Cons. | Operating income |
| Ordinary income | ¥4.6bn | 2018-04-01 → 2019-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.3bn | 2017-04-01 → 2018-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.3bn | 2016-04-01 → 2017-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.4bn | 2015-04-01 → 2016-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.2bn | 2014-04-01 → 2015-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥5.2bn | 2018-04-01 → 2019-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.6bn | 2017-04-01 → 2018-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.6bn | 2018-04-01 → 2019-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.3bn | 2017-04-01 → 2018-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.0bn | 2016-04-01 → 2017-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.3bn | 2015-04-01 → 2016-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.3bn | 2014-04-01 → 2015-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥3.8bn | 2018-04-01 → 2019-03-31 | Cons. | Profit loss |
| Net income | ¥2.4bn | 2017-04-01 → 2018-03-31 | Cons. | Profit loss |
| Total assets | ¥120.1bn | at 2019-03-31 | Cons. | Assets |
| Total assets | ¥117.5bn | at 2018-03-31 | Cons. | Assets |
| Total assets | ¥120.3bn | at 2017-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥117.7bn | at 2016-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥118.0bn | at 2015-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥39.8bn | at 2019-03-31 | Cons. | Liabilities |
| Total liabilities | ¥36.7bn | at 2018-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥80.3bn | at 2019-03-31 | Cons. | Net assets |
| Net assets / equity | ¥80.8bn | at 2018-03-31 | Cons. | Net assets |
| Net assets / equity | ¥81.9bn | at 2017-03-31d | Cons. | Net assets |
| Net assets / equity | ¥79.6bn | at 2016-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥81.4bn | at 2015-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥11.2bn | at 2019-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.1bn | at 2018-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥11.2bn | at 2019-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.8bn | at 2018-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.6bn | at 2017-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.8bn | at 2016-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥16.3bn | at 2015-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.8bn | 2018-04-01 → 2019-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.9bn | 2017-04-01 → 2018-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6.7bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.6bn | 2015-04-01 → 2016-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.3bn | 2014-04-01 → 2015-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥5.5bn | 2018-04-01 → 2019-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥487m | 2017-04-01 → 2018-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.8bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.5bn | 2015-04-01 → 2016-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥4.7bn | 2014-04-01 → 2015-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥64m | 2018-04-01 → 2019-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.2bn | 2017-04-01 → 2018-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.0bn | 2016-04-01 → 2017-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.4bn | 2015-04-01 → 2016-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.5bn | 2014-04-01 → 2015-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥210.34 | 2018-04-01 → 2019-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥130.29 | 2017-04-01 → 2018-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥109.59 | 2016-04-01 → 2017-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥121.82 | 2015-04-01 → 2016-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥115.06 | 2014-04-01 → 2015-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥4,598.89 | at 2019-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,450.92 | at 2018-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,329.25 | at 2017-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,075.2 | at 2016-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥4,066.04 | at 2015-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 64.3% | at 2019-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.3% | at 2018-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.9% | at 2017-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.4% | at 2016-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.8% | at 2015-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 4.6% | 2018-04-01 → 2019-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2017-04-01 → 2018-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.6% | 2016-04-01 → 2017-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2015-04-01 → 2016-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.0% | 2014-04-01 → 2015-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,964 | at 2019-03-31 | Cons. | Number of employees |
| Employees | 1,875 | at 2018-03-31 | Cons. | Number of employees |
| Employees | 1,870 | at 2017-03-31d | Cons. | Number of employees |
| Employees | 1,796 | at 2016-03-31d | Cons. | Number of employees |
| Employees | 1,705 | at 2015-03-31d | Cons. | Number of employees |
| Revenue | ¥40.6bn | 2018-04-01 → 2019-03-31 | Standalone | Net sales |
| Revenue | ¥38.8bn | 2017-04-01 → 2018-03-31 | Standalone | Net sales |
| Revenue | ¥36.4bn | 2016-04-01 → 2017-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥35.2bn | 2015-04-01 → 2016-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥35.5bn | 2014-04-01 → 2015-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.1bn | 2018-04-01 → 2019-03-31 | Standalone | Operating income |
| Operating income | ¥2.1bn | 2017-04-01 → 2018-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.2bn | 2018-04-01 → 2019-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥3.0bn | 2017-04-01 → 2018-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.8bn | 2016-04-01 → 2017-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2015-04-01 → 2016-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.8bn | 2014-04-01 → 2015-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.3bn | 2018-04-01 → 2019-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥4.1bn | 2017-04-01 → 2018-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.0bn | 2018-04-01 → 2019-03-31 | Standalone | Profit loss |
| Net income | ¥3.3bn | 2017-04-01 → 2018-03-31 | Standalone | Profit loss |
| Net income | ¥1.7bn | 2016-04-01 → 2017-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.4bn | 2015-04-01 → 2016-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.1bn | 2014-04-01 → 2015-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥84.6bn | at 2019-03-31 | Standalone | Assets |
| Total assets | ¥81.7bn | at 2018-03-31 | Standalone | Assets |
| Total assets | ¥82.8bn | at 2017-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥79.4bn | at 2016-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥78.9bn | at 2015-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥29.3bn | at 2019-03-31 | Standalone | Liabilities |
| Total liabilities | ¥24.1bn | at 2018-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥55.3bn | at 2019-03-31 | Standalone | Net assets |
| Net assets / equity | ¥57.6bn | at 2018-03-31 | Standalone | Net assets |
| Net assets / equity | ¥58.0bn | at 2017-03-31d | Standalone | Net assets |
| Net assets / equity | ¥56.3bn | at 2016-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥59.0bn | at 2015-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.2bn | at 2019-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.9bn | at 2018-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥114.76 | 2018-04-01 → 2019-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥183.6 | 2017-04-01 → 2018-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.25 | 2016-04-01 → 2017-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.01 | 2015-04-01 → 2016-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥54.43 | 2014-04-01 → 2015-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥50 | 2018-04-01 → 2019-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2017-04-01 → 2018-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥8 | 2016-04-01 → 2017-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥8 | 2015-04-01 → 2016-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥8 | 2014-04-01 → 2015-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,293.74 | at 2019-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,287.96 | at 2018-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,168.42 | at 2017-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,978.8 | at 2016-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,046.35 | at 2015-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 65.4% | at 2019-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.5% | at 2018-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.1% | at 2017-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.9% | at 2016-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.8% | at 2015-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.5% | 2018-04-01 → 2019-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2017-04-01 → 2018-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.9% | 2016-04-01 → 2017-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.5% | 2015-04-01 → 2016-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.9% | 2014-04-01 → 2015-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 17,000,000 | at 2019-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 20,987,000 | at 2018-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,939,000 | at 2017-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,939,000 | at 2016-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 104,939,000 | at 2015-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 768 | at 2019-03-31 | Standalone | Number of employees |
| Employees | 739 | at 2018-03-31 | Standalone | Number of employees |
| Employees | 719 | at 2017-03-31d | Standalone | Number of employees |
| Employees | 710 | at 2016-03-31d | Standalone | Number of employees |
| Employees | 692 | at 2015-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 76
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2018-04-01 → 2019-03-31 | ¥22m |
| Reconciling Itemsreconciling | depreciation | 2018-04-01 → 2019-03-31 | ¥145m |
| Reconciling Itemsreconciling | revenue | 2018-04-01 → 2019-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2018-04-01 → 2019-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | segment assets | at 2019-03-31 | ¥14.5bn |
| Reconciling Itemsreconciling | segment profit | 2018-04-01 → 2019-03-31 | −¥2.3bn |
| Chemicalreportable segment | capex | 2018-04-01 → 2019-03-31 | ¥7.6bn |
| Chemicalreportable segment | depreciation | 2018-04-01 → 2019-03-31 | ¥2.9bn |
| Chemicalreportable segment | employees | at 2019-03-31 | 1626 pure |
| Chemicalreportable segment | revenue | 2018-04-01 → 2019-03-31 | ¥82.5bn |
| Chemicalreportable segment | revenue external | 2018-04-01 → 2019-03-31 | ¥81.3bn |
| Chemicalreportable segment | revenue intersegment | 2018-04-01 → 2019-03-31 | ¥1.2bn |
| Chemicalreportable segment | segment assets | at 2019-03-31 | ¥92.1bn |
| Chemicalreportable segment | segment profit | 2018-04-01 → 2019-03-31 | ¥6.3bn |
| Medicine And Healthcarereportable segment | capex | 2018-04-01 → 2019-03-31 | ¥220m |
| Medicine And Healthcarereportable segment | depreciation | 2018-04-01 → 2019-03-31 | ¥180m |
| Medicine And Healthcarereportable segment | employees | at 2019-03-31 | 268 pure |
| Medicine And Healthcarereportable segment | revenue | 2018-04-01 → 2019-03-31 | ¥8.4bn |
| Medicine And Healthcarereportable segment | revenue external | 2018-04-01 → 2019-03-31 | ¥8.3bn |
| Medicine And Healthcarereportable segment | revenue intersegment | 2018-04-01 → 2019-03-31 | ¥141m |
| Medicine And Healthcarereportable segment | segment assets | at 2019-03-31 | ¥13.6bn |
| Medicine And Healthcarereportable segment | segment profit | 2018-04-01 → 2019-03-31 | ¥376m |
| —segment total | capex | 2018-04-01 → 2019-03-31 | ¥7.8bn |
| —segment total | depreciation | 2018-04-01 → 2019-03-31 | ¥3.0bn |
| —segment total | revenue | 2018-04-01 → 2019-03-31 | ¥90.9bn |
| —segment total | revenue external | 2018-04-01 → 2019-03-31 | ¥89.5bn |
| —segment total | revenue intersegment | 2018-04-01 → 2019-03-31 | ¥1.4bn |
| —segment total | segment assets | at 2019-03-31 | ¥105.6bn |
| —segment total | segment profit | 2018-04-01 → 2019-03-31 | ¥6.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2018-04-01 → 2019-03-31 | ¥7.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2018-04-01 → 2019-03-31 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2018-04-01 → 2019-03-31 | ¥90.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2018-04-01 → 2019-03-31 | ¥89.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2018-04-01 → 2019-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2019-03-31 | ¥105.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2018-04-01 → 2019-03-31 | ¥6.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2017-04-01 → 2018-03-31 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2017-04-01 → 2018-03-31 | ¥3m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2017-04-01 → 2018-03-31 | ¥674m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2017-04-01 → 2018-03-31 | ¥674m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2017-04-01 → 2018-03-31 | ¥16m |
| Reconciling Itemsreconciling | capex | 2017-04-01 → 2018-03-31 | ¥13m |
| Reconciling Itemsreconciling | depreciation | 2017-04-01 → 2018-03-31 | ¥135m |
| Reconciling Itemsreconciling | revenue | 2017-04-01 → 2018-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2017-04-01 → 2018-03-31 | −¥1.4bn |
| Reconciling Itemsreconciling | segment assets | at 2018-03-31 | ¥19.5bn |
| Reconciling Itemsreconciling | segment profit | 2017-04-01 → 2018-03-31 | −¥2.0bn |
| Chemicalreportable segment | capex | 2017-04-01 → 2018-03-31 | ¥3.9bn |
| Chemicalreportable segment | depreciation | 2017-04-01 → 2018-03-31 | ¥2.6bn |
| Chemicalreportable segment | revenue | 2017-04-01 → 2018-03-31 | ¥79.0bn |
| Chemicalreportable segment | revenue external | 2017-04-01 → 2018-03-31 | ¥77.6bn |
| Chemicalreportable segment | revenue intersegment | 2017-04-01 → 2018-03-31 | ¥1.3bn |
| Chemicalreportable segment | segment assets | at 2018-03-31 | ¥85.3bn |
| Chemicalreportable segment | segment profit | 2017-04-01 → 2018-03-31 | ¥6.6bn |
| Medicine And Healthcarereportable segment | capex | 2017-04-01 → 2018-03-31 | ¥67m |
| Medicine And Healthcarereportable segment | depreciation | 2017-04-01 → 2018-03-31 | ¥249m |
| Medicine And Healthcarereportable segment | revenue | 2017-04-01 → 2018-03-31 | ¥9.0bn |
| Medicine And Healthcarereportable segment | revenue external | 2017-04-01 → 2018-03-31 | ¥8.9bn |
| Medicine And Healthcarereportable segment | revenue intersegment | 2017-04-01 → 2018-03-31 | ¥60m |
| Medicine And Healthcarereportable segment | segment assets | at 2018-03-31 | ¥12.7bn |
| Medicine And Healthcarereportable segment | segment profit | 2017-04-01 → 2018-03-31 | ¥132m |
| —segment total | capex | 2017-04-01 → 2018-03-31 | ¥4.0bn |
| —segment total | depreciation | 2017-04-01 → 2018-03-31 | ¥2.9bn |
| —segment total | revenue | 2017-04-01 → 2018-03-31 | ¥88.0bn |
| —segment total | revenue external | 2017-04-01 → 2018-03-31 | ¥86.5bn |
| —segment total | revenue intersegment | 2017-04-01 → 2018-03-31 | ¥1.4bn |
| —segment total | segment assets | at 2018-03-31 | ¥98.0bn |
| —segment total | segment profit | 2017-04-01 → 2018-03-31 | ¥6.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2017-04-01 → 2018-03-31 | ¥4.0bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2017-04-01 → 2018-03-31 | ¥2.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2017-04-01 → 2018-03-31 | ¥88.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2017-04-01 → 2018-03-31 | ¥87.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2017-04-01 → 2018-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2018-03-31 | ¥98.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2017-04-01 → 2018-03-31 | ¥6.7bn |
| Chemicalreportable segment | employees | at 2019-03-31 | 698 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,882
| Item | Context | Value | Unit |
|---|---|---|---|
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.471 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 1626 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 225 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 268 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 48 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 70 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 2 | |
| Number of employees | CurrentYearInstant | 1964 | |
| Average number of temporary workers | CurrentYearInstant | 275 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 768 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 50 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 38.6 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 14.6 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 6026589 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 698 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 48 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 70 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 2 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 768 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 50 | |
| Research and development expenses research and development activities | CurrentYearDuration | 2951000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 2815000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 136000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 7844000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00780-000ChemicalReportableSegmentsMember | 7601000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E00780-000MedicineAndHealthcareReportableSegmentsMember | 220000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 17000000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 17000000 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 17000000 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 17000000 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 30 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 27 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 168 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 129 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 2 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 3983 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 4339 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 65093 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 1053 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 35664 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 36282 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 4 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 31305 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 169401 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 59900 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.3843 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |